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ABSTRACT OF THE THESIS 
 
Identification of a Novel Endogenous Small RNA Pathway Specifically Targeting 
the 3’ UTRs of mRNAs 
 
 
by 
 
 
James W.J. Randolph 
 
Master of Science, Graduate Program in Genetics, Genomics and Bioinformatics 
University of California, Riverside, June 2019 
Dr. Weifeng Gu, Chairperson 
 
We are reporting a novel WAGO small RNA pathway which specifically targets 
the 3’ UTR of hundreds of functionally important genes. In C. elegans, endogenous small 
RNAs, 22G-RNAs, bind Argonautes to regulate almost all germline genes. There are two 
major 22G-RNA-mediated pathways in C. elegans germline cells. One is mediated by 
Argonaute CSR-1 and plays important roles in chromosome segregation and embryonic 
development; the other is mediated by multiple Argonautes, WAGOs, and play critical 
roles in silencing transposons, pseudogenes, viruses, and some functional genes. In all 
these small RNA pathways, 22G-RNAs are generated by RNA-dependent RNA 
polymerases (RdRPs) using mRNAs and other RNAs as templates. Usually these 22G-
RNAs are generated from both coding regions and UTRs of RNAs. Here we are reporting 
a novel small RNA pathway which specifically targets the 3’ UTRs of hundreds of genes, 
many of which have been well studied and play important roles in germline and 
embryonic development. Our preliminary results indicated that these genes are 
targeted both by CSR-1 and WAGO Argonautes. However, CSR-1 targets the 5’ UTRs, 
 vii 
 
coding regions and 3' UTRs, while the WAGO Argonautes only target the 3’ UTRs. 
Interestingly, the WAGO-22Gs are not dependent on rde-3, which is usually required for 
generating 22Gs in other WAGO-dependent pathways including exogenous RNAi 
pathways. Our RNA-seq results suggest that the CSR-1 22G-RNAs may be involved in 
silencing the target RNAs. We are currently using genetics, high-throughput sequencing 
and ribosome profiling to investigate why WAGO 22Gs are only generated from the 3’ 
UTR regions and if these small RNAs are involved in regulating mRNA and/or translation. 
We are also analyzing if these 22G-RNAs affects miRNA-mediated gene regulation at the 
3’UTR of RNAs, In all, we are reporting a novel WAGO-mediated 22G pathway which 
specifically targeting the 3’UTR of hundreds of functional genes and this pathway is 
different from the canonical WAGO pathway since RDE-3 is not required for the 22G 
biogenesis and this pathway regulates CSR-1 targets. 
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Introduction 
 
siRNA and RNAi 
 
 The biogenesis of various small ribonucleic acids (RNAs) and their use within 
RNA interference (RNAi)-related mechanisms has been identified in a wide variety of 
organisms, ranging from plants to Caenorhabditis elegans (C. elegans) (1, 2, 4, 9, 15). 
RNAi is the name given to the cellular process that utilizes these small RNAs in a dose 
dependent manner to silence gene expression at transcriptional and/or posttranscriptional 
levels (Figure 1). This process could be a temporary effect and has been seen to affect 
cells outside of the original silencing event (4). A number of factors contribute to the 
identification of the various small RNA classes, ranging from the method of biogenesis, 
the argonaute (AGO) protein that the small RNA binds to, and the way the small RNA 
regulates or functions within the cells of the organism (2). These small RNAs range from 
sizes between 21-26 nt in length (15). The shorter of these small RNAs, 21-22nt, have 
been shown to participate in mRNA degradation (4, 9). While the larger, 24-26nt, 
contribute to the silencing and methylation of homologous DNA (deoxyribonucleic acid) 
within the organism in question (9). These short interfering RNAs (siRNAs) are long 
enough to induce messenger RNA (mRNA) degradation in mammalian cells but short 
enough to avoid triggering an interferon response due to their double stranded RNA 
structure (dsRNA) (4). The origin of the target genetic material used in the biogenesis of  
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these small RNAs can either be exogenous, coming from outside of the biological 
system, or endogenous, or coming from within the biological system. In C. elegans, small 
RNA products of RNA dependent RNA polymerase (RdRP) are referred to as 22G due to 
their prevalence of being 22 nucleotides in length with a 5’ guanosine (1,2). Originating 
from coding genes, transposons, pseudogenes, and non-annotated loci; these 22G RNAs 
Figure 1: Simplified representation of the biogenesis of 22G siRNA within the germline of C. 
elegans. 
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are found predominantly within the germline and target 50% of the currently annotated 
genome of C. elegans (2) (Figure 1). 
siRNA Roles in Human Diseases 
 
A group of 22nt small RNAs, siRNAs, have anti-viral properties in many non-
mammalian species using a process called RNA interference. Within the past couple of 
decades, these siRNAs and the RNAi pathway, have shown great promise in the realm of 
various therapeutic and anti-viral applications for humans. Viruses such as Hepatitis B, 
Influenza, and Human Papillomavirus (HPV) to name a few, have all been shown to be 
interrupted by the introduction of siRNA treatment (9). Targeting the viral gene 
expression of oncoprotein E6/7 or nucleocapsid protein (NP) using siRNA could lead to 
effective therapies for viruses such as HPV and influenza respectively. While targeting 
the chemokine receptor CXCR4 and CCR5 within a patient's own B cells could block the 
Human Immunodeficiency Virus (HIV) from ever entering the hosts B cells and 
effectively preventing its replication (9). Now siRNAs are not limited to antiviral uses, 
they also have the promise to change the face of cancer therapy by completely revamping 
chemotherapy. The MDR1 (multiple drug resistance) gene on the cancer cells, which is 
responsible for the overexpression of P-glycoproteins, is used by the cancer cells to 
remove the various chemotherapeutic drugs out of the cells. Targeting this gene could 
lead to a drastic improvement to the overall effectiveness to chemotherapy (9). 
Decreasing or silencing the expression of certain oncogenes may also be possible. For 
instance, inhibiting the expression of PLK1 or u-PA would prevent the cancer cells to 
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block the apoptosis signaling and reduce the movement and proliferation of tumors 
respectively (9). Neurodegenerative diseases also could benefit from siRNAs and RNAi. 
There are eight known neurodegenerative diseases that are caused by the trinucleotide 
CAG repeat, Huntington's disease and spinobulbar muscular atrophy are some common 
examples of these diseases. Using RNAi these diseases can be managed by targeting the 
gene that is being expressed with siRNA to decrease of inhibit the expression of the 
mutant allele (9). So, by using endogenous or exogenous targets for the creation of these 
siRNAs, various new strategies can be developed to combat viruses, genetic disorders, 
and cancer in ways that a decade ago would have not seemed possible. The study and 
discovery of new pathways and families of siRNAs could very well lead to the next big 
medical therapy.  
Argonaute 
 
 As stated previously, the small RNA in the RNAi process is bound to a protein 
called argonaute. This protein is a core effector in all RNAi processes (2). Argonaute 
proteins are found in a variety of organisms and within those organisms the argonautes 
vary in location, function and targets (2, 6, 7, 18). Using the siRNAs as a guide, the 
argonaute proteins can target a specific complementary sequence within the cells to 
perform a specific action, which varies depending upon the argonaute being bound (2). In 
C. elegans there are currently twenty-seven known argonaute proteins found in either the 
germline or somatic cells (11). These argonautes bind to 22G siRNAs that are antisense 
to their intended targets, and perform various tasks dependent upon the argonaute they 
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are bound too. For the purposes of this paper two argonautes were focused on, CSR-1 and 
WAGO family. 
WAGO Family 
 
 Worm-specific argonautes (WAGO) are a group of argonautes found within C. 
elegans. This family of argonautes is found in both the somatic and at least one role 
within germline cells, with multiple WAGO-dependent pathways existing (1, 2). WAGO 
22G RNAs come from 2911 non-functional genes and bind to the entire WAGO family, 
WAGO 1 through 12 (data not shown). The WAGO family is known to silence 
transposons, pseudogenes, cryptic loci and certain genes in both the cytoplasm and the 
nucleus (1, 2). As of now there are twelve identified members of the WAGO family (2). 
Though this may not be the entirety of the WAGO family it is believed that not all of 
these other possible argonautes are functional, possibly due to them being pseudogenes 
that have lost their functions over time (2). These twelve WAGO proteins are needed for 
the production of the germline 22G siRNA’s in C. elegans. It was found that in a deletion 
mutant strain targeting all twelve WAGO proteins lead to undetectable levels of germline 
WAGO 22G RNA’s (2).  
CSR-1 
 
 There are two distinct argonaute based pathways within the germline of C. 
elegans, one WAGO based and the other based in CSR-1 (Chromosome-Segregation and 
RNAi deficient). Unlike the WAGO family argonautes that are found within both the 
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somatic and germline cells, the CSR-1 argonaute has so far only been found in the 
germline cells of C. elegans (1, 2). Where the WAGO family argonautes has some 
function in the biogenesis of the 22G siRNA in the germline, the CSR-1 argonaute binds 
to the majority, if not all, the endogenous germline-expressed genes (1). These 22G 
RNAs originate from 3659 functional genes and do not require RDE-3 or MUT-7 for 
biogenesis (Data not shown). When bound to siRNA the CSR-1 argonaute does not seem 
to silence their intended target (2). Instead of silencing targets CSR-1 may actually 
prevent the silencing pathways of PRG-1 and WAGO family argonautes. CSR-1 is 
needed to promote the expression of male specific germline genes, males become 
infertile over the course of multiple generations of not paternal CSR-1 activity. These 
CSR-1 argonautes small RNAs also seem to act as a memory of previous germline 
expression to protect the endogenous genes from piRNAs (piwi-interacting RNA), which 
indirectly helps with the scanning of foreign sequences of dsRNA (1). Alongside its role 
with 22G siRNA CSR-1 may also have a role with regulating the transcription of its own 
target genes. When mRNA reads were analyzed from a homozygous csr-1 deletion 
mutant it was found that a group of over 100 mRNA transcripts were upregulated  
(Figure 2). This data suggested the role of CSR-1 in the mRNA regulation of its own 
gene targets.  
C. elegan Model Organism 
 
 Nematodes have been used in science in some capacity since the 1890’s, 
originally using the parasitic members. The switch to the free-living nematodes in 1900’s 
 7 
 
lead to the organism becoming much easier to use (13). This meant that instead of 
needing a host to allow the nematode to grow, they instead could grow on a enriched 
media plate. The initial draw to this organism was not for the study of molecular biology 
but for its reproduction and development. Sydney Brenner is credited with starting the 
popularity of using free-living nematodes, beginning in 1974, for use within molecular 
biology (13). The success of Brenner’s work, the ability to store strains indefinitely, the 
ease of growing these nematodes, and more lead to the rapid adoption of this model 
organism in the years following. C. elegans has gone on to be used to research into 
molecular, cellular, physiological, and behavior (13).  Since 2002, six Nobel Prizes have 
been awarded to labs that used C. elegans as the model organism, which just goes to 
show the power and success this organism has within the field of science (16). This study 
is done within the C. elegans model organism due to its power when studying RNAi  
pathways. Mello and Fire discovered RNAi within C. elegans and was awarded the Nobel 
prize for it in 2006 and it is their work that helped to set the foundation of this study (16). 
 8 
 
 
Figure 2: Each dot on the plots represents a single gene. A) Plot representing the mRNA reads in a csr-1 
mutant. The circled portion are mRNA reads that have been upregulated in the csr-1 mutant. B) Plot of the 
22G reads between a WT and csr-1 mutant, showing the decrease in overall 22G small RNA reads in the 
csr-1 mutant. C) Plot of the 22G small RNA reads in the CDS of csr-1 mutant compared to that of WT, 
obvious downregulation occurring. D) Plot of the 22G small RNA reads between the csr-1 mutant and WT 
in the 3’ UTR showing an upregulation in the csr-1 mutant.  
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In previous work done by Dr. Weifeng Gu’s lab within the model organism C. 
elegans, a novel small RNA pathway has been identified through the presence of 
unpredicted 22G small RNA reads being located in the 3’ UTR. When the 22G small 
RNAs were mapped to CSR-1 target genes the downregulation is noticeable. However, 
when this data for the CSR-1 gene targets is split between the coding regions (CDS) and 
the 3’ untranslated regions (UTR) a new pattern is able to be seen. The CDS matches the 
observed pattern from the combined graph of both the CDS and 3’ UTR (Figure 2C). 
Where the pattern changes in when the 3’ UTR is seen isolated, many of the reads now 
appear to be upregulated in the absence of the assumed argonaute that would regulate and 
load these 22G small RNA (Figure 2D). All of this data was found using high throughput 
sequencing of small RNA. In this previous research it was found that it was 22G small 
RNA reads in the 3’ UTR of CSR-1 dependent genes, and these reads were not decreased 
in the csr-1 mutant background (Figure 3A & B). As it was assumed that the entirety of 
the CSR-1 dependent genes would have reads decreased this raised many new questions 
about these 22G small RNAs. First, if CSR-1 is not the argonaute that is loading these 
22G small RNAs, then what another germline based argonaute is? And second, since the 
function of the 22G small RNA is heavily dependent upon the argonaute that it is bound 
to, what is the function and target(s) of these 3’ UTR 22G small RNAs? These are the 
two primary questions the following research hopes to uncover. 
 
 
 11 
 
Methods 
 
Growth of C. elegans 
 
 The general maintenance and growth of C. elegan nematodes is described in detail 
on WormBase (3). Below are the methods, including the various tables that contain the 
recipes for various buffers and media, used given the tools available within the lab using 
the information on WormBase as a foundation. 
 
 
 
 
Table 1: A) Nematode growth media is the basis of all growth media used. The creation is split onto two 
major steps, the first being the creation of the media and then autoclaving for 45 minutes on a liquid 
cycle. Second involves the addition of (need to find out what each does again). B) The potassium 
phosphate buffer used in the NGM media post-autoclaving. C) M9 buffer that is primarily used for washing 
worms and resuspending the OP50 bacterial food.  This buffer is autoclaved after being distributed into 
500 ml Pyrex bottles.  
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Creation of Nematode Growth Plates 
 
 Nematode growth media (NGM) is the base for the rest of the growth media used 
in the study (Table 1A). This media is generally made in batches of 1L, needing to 
autoclaved before pouring into the desired plate. Ensure that there is a large stir bar 
placed within the media before autoclaving, as after the autoclaving is completed the 
flask containing the NGM media is placed on an Excella E24 incubator shaker and set to 
medium high spin settling and allowed to cool down to lukewarm temperature. Once the 
media is lukewarm plates can be poured. If the plates that are going to be made are not 
simple NGM plates (i.e. Ivermectin plates, RNAi plates, etc.) then the additional 
components to those plates are added right before pouring onto the plates. A single liter 
of NGM media can produce; ~250 35mm plates, ~25 10 cm plates, ~13 150mm. Plates 
are to be stored in labeled bags or boxes at 4oC. These are then used for plating the C. 
elegans and growing at various temperatures.  
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 Growth of OP50 Food 
 
 As a means of long-term storage and ease of 
creating large batches of OP50 bacteria food, OP50 is 
frozen down as pellets and stored at -80oC. To 
accomplish this OP50 is inoculated onto a 10 cm LB 
(Lysogeny broth) agar plate, near an open flame of a 
Bunsen burner, and incubated at 37oC overnight to 
allow for proper single colonies to develop (Table 3B). 
A single colony from this plate is then used to inoculate 
100-500 ul of TB (Terrific broth) media in the 
appropriately sized flask, and near an open flame to 
maintain sterility (Table 2A). The incubation of the flasks is done within the Excella E24 
incubator shaker set to 200 rpm at 37oC until an OD (optical density) of 0.4-0.6 is 
achieved. Once this OD has been reached the bacterial is aliquoted into 1.7 ml 
microcentrifuge tubes at 500 ul per tube. These tubes are then frozen in with dry ice 
before they are placed into the -80oC freezer for long term storage. Each tube of 500 ul 
OP50 can be used to inoculate 1 L of TB media. 
 
Table 2: Terrific Broth (TB) media is 
use to grow the OP50 bacteria food 
for the nematodes. The creation of 
this broth has a pre- and post- 
autoclaving step with the latter 
requiring the addition of 100 mL 
potassium phosphate buffer to bring 
the broth up to roughly 1 L total 
volume. 
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 Near an open flame of a Bunsen burner, pour the 
contents of a thawed seed tube of OP50 into the 1 L of 
TB media (Table 2A). Setting the Excella E24 incubator 
shaker to 200 rpm at 37oC, place the now inoculated TB 
media into the shaker overnight. Target OD of the food 
should be between 0.4 to 0.6 OD, and should reach it 
after around 16 hours of growth in the shaker.  When the 
target OD has been reached there are two options to 
collect. The first option is when the OP50 is needed 
immediately. This will entail, near an open flame from a 
Bunsen burner, to pour the media into centrifuge bottles 
and spinning it down with a swing bucket rotor at 4500 rpm at 4oC for 10 minutes. After 
the spin down, the supernatant should be removed and disposed of in the biohazard 
waste, and the centrifugation step repeated until all the OP50 containing TB media has 
been pelleted into the centrifuge bottles. Using M9 buffer, and over an open flame, 
resuspend the pelleted OP50 and place into a 50ml conical tube (Table 1C). Once all of 
the resuspended pellet has been transferred to a 50ml conical tube, it is spun down using 
a fixed angle rotor at 4500 rpm for 10 minutes at 4oC. Remove the supernatant from the 
50 ml tubes and refill with clean M9 buffer. This will clean the remaining TB media from 
the OP50. Store at 4oC for less than a month. The other method to collect OP50 is used if 
the food is not needed immediately. For this method, the OP50 containing TB media is 
placed in a 4oC fridge for at least 24 hours to allow the bacteria to settle to the bottom of 
Table 3: LB media is used for 
growing bacteria other than OP50 
food. Both require autoclaving 
before use A) Base LB media in a 
liquid state mainly used for 
growing bacteria overnight in a 
shaker. B) For growing bacteria on 
plates, the same media mixture is 
used except with the addition of 
agar to allow for the media to 
solidify in the desired plates.    
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the 2L flask. When the OP50 bacteria have settled to the bottom of the flask, near an 
open flame, remove the TB solution by vacuum. TB media is removed until roughly less 
than 50 ml of TB media and bacteria remain in the flask; being careful not to remove too 
much of the precipitated bacteria in the process. The steps then mirror that of the previous 
collection method, what is left the OP50/TB mixture is then collected into one 50ml 
conical tube per 2L flask and spun down at 4500 rpm for 10 minutes at 4oC. Remove the 
supernatant and refill to 45 ml mark with fresh M9 buffer. Storage at 4oC for less than a 
month. Checking periodically to see if contaminated before use by dropping variable 
dilutions of the OP50 onto an empty 10cm plate let stay at room temperature overnight 
and then check for contamination growth using a microscope. 
Immunoprecipitation 
 
The sample for the immunoprecipitation consists of between 100,000 to 
1,000,000 gravid adult worms. These worms need to be cleaned with M9 buffer (Table 
1C). This is done as many times as needed to remove the bacterial debris and other 
possible contaminants. Once all debris has been removed from the tube containing the 
worms, lysis buffer (Table 4B) is added at the same volume as the worm pellet. This 
usually falls around 1-2 ml. Using a tissue tearor, sheer the worms at speed eight for 
between seven to ten minutes. Check to see if the worms have been properly sheared by 
placing 1 ul drop on the lid of a plate and check with a microscope for cuticles of all the 
worms are twisted  
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or in pieces. Centrifuge the teared samples at 
200000 xg for fifteen minutes at 4oC. The 
supernatant is collected into a fresh tube 
avoiding the pellet as that contains the 
sheared cuticles.  
 
A PVDF (Polyvinylidene Fluoride) 
low binding filter is used to clean the sample 
further. Ensure that the syringe is firmly 
attached to the filter to prevent the likelihood 
of the sample from leaking. A Bradford assay can be performed to quantify the protein, 
however the average yield for one million adult gravid worms is 20 mg of protein. For 
the remainder of the protocol, one to two mg is required.  
 
Clean 40 ul of anti-FLAG M2 magnetic beads, from Sigma, by washing them 
with the wash buffer three times (Table 4A). When the beads have been cleaned the 
protein is added to them and allowed to rock at 4oC for an hour and a half in parafilmed 
tubes. The beads are then resuspended in 100 ul of water and 1.5 ul of 20 g/l glycogen. 
Add 100 ul of neutral phenol to each of the sample tubes and vortex those tubes for two 
minutes. Taking 1.7 ml microcentrifuge tubes centrifuge grease is added to the tubes 
using a 200 ul pipette tip; doing this for as many tubes as needed. Spinning down these 
tubes on burst in a centrifuge to allow the grease to settle on the bottoms of the tubes. The 
Table 4: Buffer recipes used in 
immunoprecipitation. A) IP wash buffer. 
Roughly 10 to 15 ml is needed per sample. B) IP 
lysis buffer. The worm pellet is resuspended with 
equal volumes of lysis buffer. Generally, this is 
between 1-2 mL of lysis buffer per sample. But 
this recipe defaults for 4ml, so about 2 samples.  
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supernatant of the tubes containing the beads is added to the tubes containing the grease. 
Tubes are then spun down at 12000 rpm for four minutes at room temperature. There will 
be three phases when the spin is complete, the top phase of the sample is collected into a 
new 1.7 ml tube. Samples are then precipitated with a 1:10 3M NaAc and 1 - 1.2 volumes 
of isopropanol. Ensure that the tubes are mixed well and have them place them in -20oC 
freezer for a minimum of thirty minutes. Samples are then spun down in a 4oC fridge for 
fifteen minutes at 13000 rpm. The pellet is cleaned with 75% ethanol and then 
resuspended in 10mM Tris-HCl. The samples can then be used in downstream 
experiments. 
Creation of Mutant Strains 
 
Days before the actual cross begins a male stock should be created. Collecting the 
OP50 bacterial food from a small 35mm nematode NGM plate and placing it in the center 
of a new 35mm plate that previously did not have OP50 bacteria food. Using an unused 
35mm plate, that has also been previously been dropped with OP50 food, decreases the 
chance of the worms migrating away from the center and instead near the streaks of 
OP50 that will form due to the collection of OP50 to the center. Taking the initial parent 
strain that is meant to be used as males in the first cross, take as many male worms as can 
be found on the initial growth plates and re-plated onto the new NGM plate with the food 
placed in the center. From the same strain that the males were collected from, plate 1.2x 
as many young adult hermaphroditic worms onto the same plate. When the 
hermaphrodites left alone the rate of males produced is close to 1:1000 in a lab setting, 
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but in the environment containing this higher population of males the rate is closer to 1:2. 
This plate is considered a male stock and will help in collecting enough male worms for 
the beginning of the cross. 
 
The two strains that will be used in the cross are to have been grown onto between 
ten to twenty small 35mm NGM plates before use in the cross. Though more worms can 
be grown on larger plates, like 150mm and 10cm plates, these 35mm plates make it 
significantly easier to search for the male worms and properly aged hermaphroditic 
worms. To begin the cross, another 35mm plate has its OP50 bacterial food collected 
towards the center of the plate just as is done for the male stock plates. From the male 
stock, created in previous days, add as many males as can be found on the plate with the 
centrally placed OP50. Following the addition of the male worms, 1.2x young adult 
hermaphroditic worms are added. The hermaphroditic worms should not be from the 
same strain as the males, instead should be the other strain in the cross. Any strain that 
contains a mutation that impairs movement (i.e. unc, dpy, etc.) should be used as the 
hermaphrodites. If those strains are used as the males, which would be required to move 
to reproduce with the plated hermaphrodites, the chance of a successful cross will be 
drastically reduced. This process of plating males and then 1.2x the number of 
hermaphrodites continues until the target strain is believed to be reached.  
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Brood Size 
 
Grow the selected worm strains until they are at larval stage 4 (L4). This would 
mean that the hermaphroditic worms are almost at the adult stage before they have a fully 
developed vulva and have yet to begin laying eggs. Single ~25 of the L4 stage 
hermaphrodites onto numbered 35mm plates containing the appropriate growth media. 
Allow the worms to stay on the plates for a full 24 hours. When the 24 hours is up, re-
plate the adult hermaphroditic worms onto new numbered 35mm plates. Save the plates 
from the previous day along with the new plates, and wait another 24 hours. The next 
day, record the amount of hatched larval stage 1 (L1) hatched worms and the amount of 
unhatched eggs on the original numbered plates the hermaphrodites were singled onto. 
Just like the previous day, re-single the hermaphroditic worms onto another set of new 
numbered 35mm plates while keeping the previous plates for counting, wait for another 
24 hours. When the 24 hours are up, once more count and record the number of hatched 
L1 worms and unhatched eggs from each numbered plate. The singled hermaphroditic 
worms are also moved to another set of new numbered 35mm plates, with the previous 
numbered plates being saved for counting the next day. Wait for another 24 hours, after 
this wait the worms should have stopped laying eggs all together so the plates containing 
the worms now should only contain the hermaphrodites after the 2 hours. When the last 
24-hour wait is finished, count the amount of L1 worms and unhatched eggs are on the 
numbered plates. Also, the plates containing the singled hermaphroditic worms should be 
checked for any eggs, if there are then the process should be continued for another day.  
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Ribosomal Profiling 
 
The protocol for the ribosomal profiling was provided by Dr. Yonghui Zhao, a 
post-doctoral researcher in Dr. Xuemei Chen’s lab. Slight modifications have been made 
to accommodate for the use of C. elegans instead of Arabidopsis (10). Mainly in the area 
of sample preparation and analysis of the produced graph. Below goes through the 
protocol detail as done within Dr. Weifeng Gu’slab. 
 
Sucrose Gradients  
 
Nine sucrose gradients are created after each run of the protocol. These sucrose 
gradients are considered discontinuous gradients due to the concentration of sucrose 
being nonconsecutive (i.e. 15%, 30% to 45% instead of 10%, 11%, and 12%). Due to 
their thinner walls, polypropylene centrifuge tubes are used and pre-cooled in a -80oC 
freezer. The bottom 60% sucrose layer is created in a 50ml conical tube while on ice and 
is vortexed to ensure that it is thoroughly mixed (Table 5). Using serological pipettes, add 
the solution slowly to the centrifuge tubes. If the solution is added too quickly bubbles 
will form in the sucrose layer which will cause the fraction collector to register “spikes” 
on the graph created through the Brendel software. Placing a sheet of parafilm over the 
Table 5: Recipe for the different layers of the sucrose gradients. This makes nine discontinuous sucrose 
gradients that need to be stored at -80oC.   
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openings of each of the 
centrifuge tubes, place them 
back into the -80oC freezer for 
an hour. During this hour the 
next layer is created, 45% 
sucrose, and is left on ice until 
the hour is finished (Table 5). 
Once again using a serological 
pipette, slowly add the 45% 
sucrose solution to the 
centrifuge tubes that should now 
have a frozen bottom layer. 
Cover the centrifuge tubes again 
with parafilm and place into the 
-80oC for another hour. The creation of the 30% sucrose layer is then created in this time 
as was done with the 45% sucrose solution (Table 5). The same process is repeated until 
the final 15% sucrose solution is created and poured (Table 5). The sucrose gradients can 
be stored indefinitely in the -80oC freezer. Due to the preparation time of these gradients, 
they are prepared at least a day ahead of the actual ribosomal profiling protocol. 
 
 
Table 6: Recipes for the buffers needed through the ribosomal 
profiling protocol. These are all to be made the day before the 
protocol.  DTT, c0mplete cocktail, cycloheximide, and 
chloramphenicol are added right before the use of the buffer in the 
protocol.  
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Sample Preparation and Fraction Collection 
 
 Preparation for the ribosomal profiling begins with the growth of the mutant 
strain. Ensuring that the proper growth media is being used for the specific strain, grow 
650,000 or more young adult stage worms. The stage is critical, at this point in their 
development the worms have yet to start producing eggs which means that the rRNA 
(ribosomal RNA) collected at the end of the experiment is collected solely from the adult 
worms and not the next generation. These young adult worms are then cleaned by 
spinning them down in a 15 ml conical tube at 4000 rpm for 30 seconds to a minute until 
the solution is clear containing only the worms. If this is not enough than the worms can 
be precipitated once again, using M9, until the solution is clear (Table 1C). To do this, 
add M9 to the 10 ml mark on the 15 ml conical tube and vortex. Allow the worms to 
settle to the bottom of the tube before carefully vacuuming out the M9 buffer, ensuring 
not to take up any of the worms. Repeat this process until the solution is clear. As with 
the importance of the development state of the worms, cleaning the worms ensures that 
no bacterial contamination will be present during the collection of the rRNA.  
  
 After collecting and cleaning the worms the next step is to lyse the worms. 
Remove as much of the M9 buffer from the 15 ml tube as possible and replace it with 
8ml of the polysome extraction buffer (PEB)(Table 6A). Ensuring that the tube stays 
enclosed in ice, tear the worms for seven minutes on speed eight. Check under a 
microscope to see if the cuticle of the worms has been complete sheared, if not continue 
to tear until the worms are sheared. If this is not done, then the yield of rRNA will be too 
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low to proceed with the final steps of the protocol. To remove the cuticle and other 
unwanted particulate from the solution centrifuge the 15ml tube at 16000 xg for 10 
minutes. Transferring the supernatant to a new 15ml tube, centrifuge again at 16000 xg 
for 10 minutes. During each of these steps a pellet should form, do not disturb this pellet 
as it contains the cuticles and other debris.  
 
 While on ice, add 8ml of the sucrose cushion to 2” polypropylene ultracentrifuge 
tubes (Table 6B). This solution is very viscous, add this solution slowly to ensure that no 
bubbles form on the cushion. Take the cleaned worm lysate and add it to the tubes 
contain the sucrose cushion. Using the remaining PEB, balance the tubes. Load the tubes 
into a Type 70TI fix angle rotor making sure that there is a clear mark on the lids of the 
tubes pointing towards the outside of the rotor to indicate which side of the tube will 
contain the pellet, and then load into the Beckman L8-70M ultracentrifuge. Setting it for 
50000 rpm at 4oC for three hours. During this time, place the discontinuous sucrose 
gradients from the -80oC storage into a 37oC incubator for 45 minutes to an hour, this is 
meant to thaw them for use in the next steps. When the gradients are thawed, making sure 
to not disturb the gradients, place them into a 4oC fridge until they are needed.  
 
 When the first round of ultracentrifugation is completed, remove the tubes from 
the rotor and make sure that the mark on the lid is still facing towards the outside of the 
rotor. Check the side of the tube matching the mark on the lid for the pellet. The pellet is 
likely to be translucent and faint but should be slightly visible under direct light, circle 
 24 
 
the pellet clearly on the tube. Vacuum the remaining PEB and sucrose cushion out of the 
tubes making sure to avoid the pellet. Take 1ml of di-water using a micropipette to clean 
the sides of the tubes and around the pellet. To wash around the pellet, hold the plunger 
still while trapping water between the pipette tip and the inside wall of the tube, slowly 
move the trapped water around the perimeter of the pellet. Do not release any water over 
the actual pellet or it will begin to dissolve and the sample will be lost. After completing 
this cleaning procedure two to three times, use the resuspension buffer to dissolve the 
pellet (Table 6C). The starting number of worms dictates the volume of buffer used in 
this step. If the number of worms is on the lower end of the scale use 400ul of buffer, if 
on the higher end then use 1 ml. This will ensure the OD260 will be in a reasonable range 
for loading onto the sucrose gradient. To calculate the OD260 for the sample take 1ul of 
the sample for use in a nanodrop, DeNovix DS-11 Spectrophotometer, and record the 
value of A260 that it provides. Take 5000OD and divide it by the OD260 that the 
nanodrop provided to get the volume of your sample you need to load onto the sucrose 
gradient. If this volume is greater than 400 ul than too much resuspension buffer was 
used. Slowly add the proper volume of the sample to the labeled sucrose gradient to 
ensure once again that there are no bubbles. Balance these gradients so there is no 
difference between any of them. Load the gradients into a SW55TI swing bucket rotor 
and then into the ultracentrifuge. Spin the gradients at 50000 rpm for 1.5 hours at 4oC.  
 
 After the ultracentrifugation of the sucrose gradient they should be immediately 
placed on ice while still within the swing buckets holders for the tubes ensuring that the 
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samples do not spill into the ice. The sucrose gradients are then loaded into a Brandel 
sucrose fraction collector. It will push fluorinert FC-40 oil through the bottom of the 
sucrose gradient containing the samples through the machine which will then use an 
attached UV spectrophotometer to detect the A260 which is then displayed in graphical 
form using software provided by Brendel. While this is happening, the fraction collector 
is distributing the sample in a set volume into 1.5ml microcentrifuge tubes dropwise. 
Collect these numerous tubes and place them on ice. Store them temporarily at -20oC, but 
for long term storage -80oC. The tubes containing the polysome are then pooled by 
taking 1/3rd of each tube into a new tube and proceeding to precipitate the sample using 
isopropanol. The resuspended samples are then able to be used in downstream protocols. 
Small RNA and mRNA Cloning 
 
Starting with the total RNA for small RNA and pelleted RNA for the mRNA 
(messenger RNA), the cloning protocols begin with 3’ ligation. Just like with starting 
material, the common mixture for the 3’ ligation changes dependent upon whether small 
RNA or mRNA is being cloned. Small RNA differs through the use of PEG-8000 
(Polyethylene glycol 8000) instead of DMSO (Dimethylsulfoxide), which is used in 
mRNA cloning, and the addition of a catalytically dead pir-1 protein (Table 7A). The 
mixture in both cases needs to be mixed well but especially in the case of the small RNA 
due to the viscous PEG-8000, the small RNA samples need to be watched while mixing 
to ensure that they are all mixed completely. DMSO and PEG-8000 is used to slow down 
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the movement of the molecules in the solution 
and help the RNA ligase bind to its target and 
increase the reactions efficiency.  When the 
samples are as homogenized as possible allow 
them to sit at room temperature for between 
two to three hours. During this incubation the 
activated linker is bound to the 3’ end of the 
target RNA. This linker is considered activated 
due to the adenosine phosphate group located at 
its 5’ end, this allows for a phosphate anhydride 
bond between the two pieces of genetic 
material to form. The use of RNA Ligase II 
(Rnl2) prevents the formation of self-ligation of 
the primers and higher efficiency over that of 
RNA ligase I. 
 
This incubation at room temperature is followed by another incubation at 65oC 
for ten minutes. After this the addition of 0.5 ul of a DNA oligo meant to bind to the 
remained of the free-floating activated oligo from the 3’ ligation step. This will prevent 
the T4 RNA ligase 1 from using the activated linker from the previous steps. The 
concentration of this oligo is different between the two versions of cloning, 5 uM for 
small RNA and 10 uM mRNA. Another incubation at 65oC for five minutes follows the 
Table 7: Recipes for the various steps of the 
small RNA cloning A) 3’ ligation, step 1 of the 
cloning procedure. B) 5’ ligation, step 2 C) 
Reverse Transcription (RT), step 3 D) PCR 
amplification of mRNA, step 4. 
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addition of the oligo. Cool the samples back down to room temperature by 0.1oC per 
second. These incubation steps are completed using a thermocycler to allow for precise 
control for cooling down.  
 
When the samples have been cooled back down to room temperature the next 
common mixture is made on ice and is meant for the 5’ ligation step (Table 7B). This 
common mixture is the same for both the small RNA and mRNA cloning protocols. ATP 
is added to this reaction for the addition of the adenosine phosphate to the 5’ end of the 
target. This adenosine phosphate is then the target of the RNA oligo creating another 
phosphate anhydride bond. An RNA oligo is used over the DNA oligo for the use in the 
next step of reverse transcription. When the common mixture is finished 9.5ul of this 
mixture is added to each of the samples. As with the 3’ ligation, mix as close to 
homozygous as the solution allows. This is then left out for two to three hours at room 
temperature.  
 
Next the samples are to be converted to DNA. This is accomplished through 
reverse transcriptase, otherwise simply known as RT. Using the RNA oligo that was 
recently bonded to the 5’ end of the target material the superscript II enzyme will use as a 
starting point to transcribe the newly formed DNA product. The common mixture is 
made the same way between the two versions of the RNA cloning (Table 7C). Adding 
4.125 ul of the common mixture into each of the samples and incubating them in a 
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thermocycler for 30 minutes at 42oC followed by 85oC for five minutes and finally a 
holding step at 4oC.  
 
The final step is polymerase chain reaction (PCR). Due to the identical ligated 
ends the chance for the formation of botched products is higher in this PCR reaction than 
in a normal PCR reaction. To work around this 0.1 uM of oligos (these oligos are 
represented as wg239 and wgnnn in Table 7) is used during the first sixteen cycles of the 
reaction. Using less oligos at the beginning of the reaction decreases the formation of 
botched products and still allows for the actual target to gain a higher concentration in the 
sample(s). An additional 0.5 uM of oligos is added to the reaction(s) for the final two 
cycles. Given the higher concentration of the target at this point in the reaction means that 
the added oligos will have a higher chance to bind to the target and amplify them over the 
botched products. Important to this step is the DNA oligo that is used as a barcode for the 
individual sample to help identify the reads later on during high throughput sequencing. 
Each oligo is a unique nucleotide sequence that binds to the end of the products, and one 
of these is used for each sample ensuring there is no overlap between samples. Each 
sample may be run multiple times through this step to help amplify the sample to a level 
that can be used downstream in throughput sequencing (Table 7D). To check for this, 
each sample is run on an 8% native PAGE gel to compare their relative intensities to that 
of the other samples in that specific set. Based on the intensities one or more PCR runs of 
a given sample may be done to get them all to have roughly the equivalent amount of 
genetic material.  
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mRNA Sample Preparations: 
 
Ribo Zero 
 
 Starting concentration of total RNA should 
be around 0.1 g/l, and will go through two initial 
protocols before mRNA cloning. The initial 
preparation step is RiboZero, also known as 
Ribominus. This process is designed to cleave the 
different subunits of rRNA into smaller, ~50 nt, 
pieces to help mitigate their possible interference 
with the mRNA cloning downstream. 
 
Table 8: A) Reagents needed for the 
completion of the Ribozero protocol.  The 
ce rRNA oligo 1 and 2 are DNA oligo sets 
that have been designed to target the 26S, 
18S, 5S and 5.8S ribosomal subunits. 10X 
annealing buffer is made with 500 mM 
Na3Citrate, pH 7.0, 100 mM MgCl2 B) 
Reagents needed for the creation of the 
reaction solution for the P1 partial digest. 
10X P1 buffer is made with 0.5M Na3 
citrate pH7, MgCl2 0.1M.  
 
 30 
 
MirVana lysis/binding buffer, parts of an industry phenol-based miRNA (micro 
RNA) isolation kit, should be placed at room temperature before beginning the protocol.  
On ice, prepare the sample by following the recipes in Table 8A. The ce rRNA oligos 1 
and 2 are premixed DNA oligo sets that have been designed to target the 26S, 18S, 5S 
and 5.8S ribosomal subunits. Once this solution has been mixed thoroughly, heat it to 
95oC for 2 minutes and then cooling the sample down to 30oC by 0.1oC every second 
using a thermocycler. This should help to degrade the rRNA enough to allow the oligos 
enough space to bind to their intended targets. When the sample has been cooled to 30oC 
add 2uM of RNase H (Ribonuclease H) to each tube, samples should now be placed at 
Figure 4: Animated simplified representation of the mRNA cloning sample preparation step, 
Ribozero. The polysome from samples collected post polysome profiling go through this 
process to remove the bound ribosome and free the mRNA they are bound too. The column 
purification portion leads to the final sample preparation step, P1 partial digest. 
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room temperature for the remainder of the protocol. RNase H is an enzyme that targets 
the hybrid molecule of RNA binding to DNA. This is important, as at this point the DNA 
oligo should be bound to the rRNA subunit at 50 nt intervals, so only these molecules 
should be cut and not the mRNA still found in the samples. Incubate the samples at 37oC 
for 50 minutes and add 1 ul of 10 U/ul CIP (Alkaline Phosphatase, Calf Intestinal) 
followed by another 20 minutes at 37oC, however the addition of CIP does not seem to 
affect the overall process so may be skipped and simple incubate for a full hour with only 
RNase H (data not shown). When the incubation is complete immediately move onto the 
next step, which entails column purification. Following the incubation, 100 ul of the 
mirVana lysis/binding buffer is added to each of the samples, mixing well. Allow the 
samples to then stay at room temperature for five minutes. This is then followed by the 
addition of 12 ul of 3M NaAc (Sodium Acetate) pH 5.2 and 34 ul of 100% ethanol and 
mixed well without the use of a pipette. Using a pipette may lead to the shearing of the 
mRNA to a degree that makes it useless in downstream applications. Transfer the 
samples onto RNA tini columns, ensuring not to disturb the filter at the bottom. These 
columns will help to isolate the RNA from other possible contaminants in the original 
sample. Spin the samples in a centrifuge at 10000 rpm for 1 minute and dump the flow 
through. Using 500 ul of 80% ethanol, wash the samples twice spinning them down in 
centrifuge at 10000 rpm for a minute for each wash. After removing the flow through 
from the last wash, centrifuge the now liquid free columns at 10000 rpm for two minutes 
to dry the columns. Replace the collection tubes from under the columns with fresh 1.7ml 
centrifuge tubes. Adding 18 ul of 95oC 2.5 mM Tris pH 8, gently to each of the columns 
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to ensure that the column is not disturbed. Wait for one minute at room temperature 
before spinning the samples at 10000 rpm for two minutes. Placing the samples on ice, 
the next preparation step is prepared. 
P1 Partial Digestion 
 
 For this protocol the entirety of what was collected from the columns in the 
previous protocol will be used. Now due to volume loss in the column the collected total 
volume is actually closer to 15 ul instead of the expected 18ul, so that will be the volume 
used to do the calculations for this protocol. Add the mixture indicated in Table 8B and 
allow to incubate at 60oC for 10 minutes in a thermocycler. The addition of P1 is meant 
to digest the mRNA in the sample to slightly smaller length, but not to completely digest 
them. The size of the mRNA directly affects the efficiency of the mRNA cloning 
protocol, the protocol favors the smaller pieces over larger. So partially digesting the 
mRNA helps to increase the efficiency of the mRNA cloning protocol. Immediately the 
samples should be placed onto ice and 1ul of 0.5 M EDTA (Ethylenediaminetetraacetic 
acid) is added. Next is a phenol chloroform extraction. Using a pipette tip, place a pea 
size amount of centrifuge vacuum grease into a 1.7ml centrifuge tube, this is done once 
per sample and is referred to as a phase lock column. Add 80 ul of H2O and 2ul glycogen 
to the sample(s), mixing well before the addition of 100 ul acidic phenol/chloroform. 
This mixture is than added to the phase lock column(s). Spin the columns at 12000 rpm 
for 4 minutes at room temperature. After this spin down three phases should be visible. 
The top phase is a liquid that will be collected to continue to isopropanol precipitation. In 
 33 
 
the middle should be the vacuum grease, and the final phase should be the phenol and 
other unwanted materials from the sample. The top phase should be collected into a fresh 
1.7ml centrifuge tube and have 10ul of 3M pH 5.2 NaAc and 80ul isopropanol added. 
Mix the solution well by inverting the tube multiple times and gently finger vortexing. 
Place he sample(s) into a -20oC freezer for at least 30 minutes. When the samples have 
been in the -20oC for the minimum 39 minutes, they are centrifuged for 15 minutes at 
12000 rpm at 4oC. A white pellet should form at one of the bottom sides of the tubes. 
The supernatant is then removed and the pellet is washed with 1mL of 75% ethanol. The 
pellet is resuspended with 10mM pH 7.5 Tris buffer between 10-15ul. This volume is 
dependent of the size of the pellet, the larger the pellet the larger the volume to 
resuspend. Next the samples are gel purified to attempt to remove as much of the rRNA 
from the samples as possible. Load the samples unto a 10% Urea PAGE gel using a two-
dye loading dye, xylene cyanol and bromophenol blue. Loading alongside the samples is 
a lab made total RNA ladder. Two pieces are cut out of the gel for each sample, one 
between 75 bp and 165 bp and the other between 165bp and 300bp. Both pieces, per 
sample, are gently dried on a Kimwipe and placed into a 1.7ml centrifuge tube. Spin 
down the tubes on burst in a centrifuge for a few seconds to get the gel pieces to the 
bottom. Using a 1 ml micropipette tip, grind the gel pieces against the walls of the 
centrifuge tube. When the gel pieces have become very fine, 750 ul of TE buffer is then 
added to each sample and the lid wrapped with parafilm and allowed to shake at room 
temperature overnight. The following day the sample(s) are spun down on burst in a 
centrifuge to have the pieces of the gel reach the bottom of the tubes. The supernatant is 
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then collected into a new 1.7 ml tube. Ensuring that all liquid is collected, while rotating 
the pipette so that the tip is against the wall of the tube, gently lift off the plunger to 
collect the liquid that is still with the gel pieces at the bottom of the tube. Depending 
upon the volume collected from the previous tube, ~75 ul of 3M NaAc, 1.5 ul of 20 ug 
glycogen and ~800 ul isopropanol is added to the samples. The tubes should be just about 
filled at this point so it is essential to work slowly as to not spin any of the mixture. Mix 
by inverting multiple times and finger vortexing. Allow the sample(s) to stay in a -20oC 
freezer for a minimum of 30 minutes followed by being centrifuged for 15 minutes at 
12000 rpm at 4oC. A pellet should form at the bottom side of the tubes. The supernatant 
is removed and the pellet washed with 75% ethanol. This wash step is followed by the 
resuspension of the pellet with ~10 l of the 3’ ligation mixture from the beginning of the 
mRNA cloning protocol.  
Results 
 
Identifying the Argonaute Loading the 3’ UTR 22G Small RNA Using 
Immunoprecipitation and High Throughput Sequencing.  
 
 There are twenty-seven argonautes in C. elegans but only a handful have been 
discovered to work within the germline, of that handful CSR-1 and the WAGO family are 
known to be there (11). Even given the large number of genes these two argonautes target 
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the overlap between the two is significantly smaller than the total pool, with only 32 
genes overlaping (data not shown). Though the WAGO family has twelve argonautes, 
only two were focused on, WAGO-1 and WAGO-9. WAGO-1 even has a known 
function within the germline localizing P-granules and gene silencing (2). WAGO-9 is 
also known as hrde-1 (heritable RNAi deficient), is seemingly found only within the 
germline of C. elegans, and abundantly expressed within these cell’s nucleus (8). This 
argonaugte has been found to play a critical role in epigenetic silencing within the 
germline genome and the inheritance of these modifications through to the next 
generation (8, 12). As apparent with the above statements, these two WAGO argonautes 
are well researched and documented within the WAGO family. It is because of this that 
they were chosen to be used in the immunoprecipitation first before any others within the 
family were attempted. 
 
 Transgenic worm strains containing one FLAG-tagged transgene for either one of 
two chosen members of the WAGO argonaute family, WAGO 1 and WAGO9, were 
Figure 5: These two images represent the reads of CSR-1 associated gene targets. The light blue represents 
the Watson strand, and the pink represents the Crick strand. Both Pgl-1 and Klp-7 are CSR-1 dependent 
genes. The reads presented are associated with the results of the immunoprecipitation of WAGO-9 and 
WAGO-1 transgeneic worm strains. 
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grown for use in this immunoprecipitation (IP) protocol. The transgenic strains are within 
a csr-1 mutant background. Meaning that these strains also do not have a functioning 
CSR-1 argonaute when homozygous. Lysates to these transgenic strains were collected 
and then had a portion of each collected lysate set aside to be used as input samples for 
each strain. The remainder of the lysate for each sample proceeded through the IP 
protocol. The 22G small RNAs that were collected from these pulled down loaded 
argonautes should reveal which of the two, if any, load these 22G small RNAs when in 
the absence of csr-1 argonaute.   
 
Using known CSR-1 dependent genes, Klp-7 and Pgl-1, the 22G RNA reads were 
analyzed through a genome browser (Figure 5). It was noticed that the coding regions are 
void of 22G small RNA reads, which is consistent with the csr-1 homozygous mutant 
background. CSR-1 argonaute loads 22G small RNAs that was created using the CDS of 
its dependent genes. This lack of CDS reads is consistent between both the WAGO-1 and 
WAGO-9 transgenic samples. However, the difference between the two samples, 
WAGO-9 and WAGO-1, is noticed not in the CDS but in the 3’ UTR. Comparing the 
input to the experimental WAGO-1 sample shows no amplification to the 3’ UTR (Figure 
5). The WAGO-9 input looks like the WAGO-1 input but the changes show in the 
experimental sample. Reads in the 3’ UTR of the WAGO-9 sample are upregulated at 
least two-fold over that of the input sample. 
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The outcome of this IP answered the first of many questions regarding this new 
22G small RNA family, what argonaute is the 22G small RNAs being loaded onto? 
Taking the analysis all together shows that WAGO-9, not WAGO-1, likely loads these 
new 22G RNAs. This is apparent due to the noticeable enrichment seen in the 3’ UTR 
regions from the experimental reads over that of the input reads for WAGO-9 sample 
from within these CSR-1 dependent genes (Figure 5). So as WAGO-9 was being pulled 
down it was loaded with members of this novel 22G small RNA family.  
C. elegan csr-1 wago-9 and csr-1 alg-5(ram2) Mutant Strain Crosses  
 
csr-1 wago-9 Double Mutant  
 
Figure 6: Simplified figure representing the creation of the csr-1 hrde-1 (wago-9) double mutant. A) The 
cross from the viewpoint of the second chromosome, where the hrde-1 mutant loci are located. B) The 
cross from the viewpoint of the csr-1 mutation which involves both the fourth and fifth chromosome due 
to the needed nT1 balancer.  
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Seeing as the CSR-1 argonaute was found to not be loading the 3’ UTR 
originating 22G small RNAs the argonaute that actually loads these small RNAs needed 
to be found. Previous immunoprecipitation work had found that it was in fact the 
WAGO-9 argonaute that loads these 3’ UTR 22G small RNAs (Figure 5). This result lead 
to the decision to use a WAGO-9 mutant in this cross over a WAGO-1 mutant. This 
double mutant containing both csr-1 and wago-9 deletions will be used to collect and 
then sequence the mRNA and small RNA, and then observe the strain for any newly 
developed phenotypes.  
 
 This cross begins with a hrde-1 (wago-9), which is represented as tm1200 in 
Figure 6, homozygous mutant and a csr-1 nT1 balanced heterozygous mutant. Viewing 
Table 9: Progeny marked with the asterisk (*) is what is used in the next crossing step. A) The progeny of 
the initial cross between the csr-1 balanced and hrde-1 (or wago-9) mutant worms. B) Progeny results of a 
sibling cross between the two viable progenies of the initial cross. C) Progeny results of the backcross using 
the selected strain from the previous sibling cross.  
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from the second chromosome, the initial cross leads to the progeny being heterozygous 
for the wago-9 deletion mutation. The cross then continues with a sibling cross, followed 
by a back cross. With three fourths of the progeny containing at least one copy of the 
tm1200 mutation in the sibling cross and half of the progeny containing at least one copy 
after the back cross. Taking the same cross and viewing it from the fourth and fifth 
chromosome shifts the focus from the wago-9 (tm1200) deletion mutation to the csr-1 
balanced mutation. The first cross between the wago-9 homozygous mutant and the 
heterozygous csr-1 mutant results in only 50% of the progeny being viable (Table 9A). 
This is due to the balancer with in the csr-1 mutant strain containing a WT (wild-type) 
copy of either a portion of the fourth chromosome, located on the balancer on the fifth 
chromosome, or a portion of the WT fifth chromosome, located on the balancer on the 
fourth chromosome. This extra copy of either chromosome when in conjunction with a 
strain that already has WT copies of these chromosomes causes a trisomy to form and a 
non-viable worm. The two viable progenies are then crossed together in a sibling cross. 
The progeny that is not exhibiting the unc phenotype is used as the male for this cross 
and contains a copy of the csr-1 deletion mutation (Figure 6). While the unc exhibiting 
progeny contains the balancer and is used as the hermaphrodite (Figure 6). The resulting 
progeny of this cross also suffer from 50% viability due to the balancer. Of the remaining 
progeny 50% contain the unc phenotype, and only half of those unc worms contain the 
wanted genotype (Table 9B). However, checking for the genotype at this stage is 
impractical as it would consume the worm. So, all the hermaphroditic worms exhibiting 
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the unc phenotype were collected and backcrossed with a male from the initial cross 
(Figure 6). This backcross helps to clear any background mutations that may have formed  
during the cross and “cleaning” up the strain. The resulting unc expressing progeny are 
singled onto new 35mm NGM plates and subjected to further screening using PCR 
(Table 9C).  
 
Through the use of various genotyping protocols for the csr-1 and wago-9 mutant 
alleles, the possible newly created mutant strains were tested. Mutant deletion allele 
tm1200 for the WAGO-9 argonaute is not essential for the development of the worms so 
its existence as a homozygous mutant is tested. The wago-9 homozygous mutant seemed 
to grow and propagate at a higher rate than that of the N2 WT worm strain, though this 
has only been observed anecdotally not tested as of yet. The csr-1 deletion mutant on the 
other hand creates non-viable offspring when it is homozygous in the current generation. 
Due to this, the csr-1 mutant should exist in the new strain in a heterozygous form paired 
with a balancer. As with the previous wago-9 deletion allele, the genotype is determined 
through a PCR protocol. Though unlike the previous deletion allele, the csr-1 deletion 
allele is expected to be heterozygous. All of these expected double mutant strains are 
created within a background of ivermectin resistance. Ivermectin resistance is made up of 
three homozygous deletion mutations that must all exist within the strain for it to have the 
resistance. The three genes that are to be deleted are avr-14, glc-1 and avr-15. To test for 
the presence of these three mutants the strains that passed the two genotyping 
experiments were plated onto small 35mm ivermectin plates and allowed to grow. These 
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plates were checked daily for the worm’s survival. This ivermectin screening process 
usually only lasts between 24-48 hours. When the screening of the possible new mutant 
strains was completed, four were discovered to be the correct genotype. These four new 
strains had phenotypes similar to that of heterozygous csr-1 mutants, slower growth rates. 
Those four that manage to survive contained the necessary three mutations for ivermectin 
resistance, alongside those of the wago-9 homozygous and csr-1 heterozygous balanced 
mutations. These four new strains were then stored in -80oC. One of these four strains 
collected after this process is then to be used in the downstream polysome profiling and 
cloning protocols 
 
When this new strain is on ivermectin, which leads to the C. elegan to possess 
both wago-9 and csr-1 in a homozygous state, a new phenotypic trait was observed. The 
hermaphroditic worms in this strain seemingly lacked the ability to develop any eggs 
within their germline. This phenotype may shine new light on a new role for WAGO-9 in 
the germline if this new phenotype persists throughout the reproductive lifespan of the 
worms. The male worms of this mutant strain seem to possess no noticeable, unexpected, 
phenotypes. Data collected from the downstream sequencing should bring to light the 
possible genes being affected to allow this phenotype to become expressed. 
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csr-1 alg-5(ram2) Double Mutant  
 
Due to ChIP (chromatin immunoprecipitation) sequencing data previously 
completed by Dr. Weifeng Gu, it was discovered that the mir-58 family miRNA shares 
the same target loci of the CSR-1 dependent gene 3’ UTR that this novel small RNA 
pathway also targets (Data not shown). The ALG-5 gene encodes a necessary protein 
found in the biogenesis of many miRNA families within C. elegans germline, including 
the miR-58 family (14). The goal was then to introduce a deletion mutant allele of the 
ALG-5 gene in a csr-1 deletion and ivermectin resistant background.  The alg-5(ram2) 
strain for this cross was provided by Dr. R.M & B.E Montgomery’s lab, while the csr-1 
mutant strain was the same lab strain used for the previous csr-1 wago-9 cross (14). A 
strain containing this double mutation will bring to light any possible role overlap or 
regulation that the miR-58 family may have with the CSR-1 argonaute.  
 
Table 10: Progeny marked with the asterisk (*) were what is meant to be used in downstream crosses. A) 
Table representing the progeny from the initial cross between the csr-1 balanced mutant strain and the alg-
5(ram2) mutant strain. Only the first part of the table is what is used in the next step due to it containing the 
csr-1 mutant allele. B) This table represents the offspring from a backcross with the progeny from the 
previous cross and the original csr-1 mutant strain.  
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 The csr-1 deletion mutant strain was used as the hermaphrodite and the alg-
5(ram2) deletion mutant was used as the male for the cross (Figure 7). This was decided 
due to the unc mutation present on the csr-1 mutant balancer. As mentioned previously in 
the cross between the csr-1 and wago-9 mutants, this unc mutation makes the movement 
of the worms to be severely hindered, so it was decided to have the alg-5(ram2) mutant 
take the position of the male as they do not have hampered movements. The results of 
this cross should have progeny containing four different genotypes. However, due to  
csr-1 having to exist with the nT1 balancer, only 50% of the progeny would be viable 
(Table 10A). This is for the same reason as described before in the csr-1 wago-9 cross. 
Of the remaining 50% of progeny that actually are viable only one is what is needed for 
the next part of the cross. The one that is used is the only one that contains the csr-1 
mutant and not the balancer containing the unc mutation. Because of the lack of the unc 
mutation, distinction between the two viable progeny is significantly easier, as the worms 
moving normally are the males to be used for the next cross. The next cross, a back cross 
Figure 7: Simplified road map to the creation of the csr-1 balanced alg-5(ram2) homozygous double 
mutant strain. The F2 progeny will be self-crossed and the offspring plated on ivermectin plates to identify 
strains homozygous for avr-14 and possibly alg-5(ram2) 
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with the same csr-1 balanced strain as the initial cross, also creates offspring with a 50% 
viability (Figure 7). Half of the viable offspring will be noticeably unc and the other half 
will not, unlike the previous cross the progeny to collect this time are those that are unc 
mutants (Table 10B). Of those worms that are unc only one combination is what is 
wanted. At this stage however, it is not possible to determine which is which. So, all unc 
worms are collected. Hermaphroditic unc progeny from this backcross are then singled 
onto 35mm NGM plates and allowed to self-cross. The progeny of this self-cross is 
plated onto ivermectin 35mm plates and observed for 24-48 hours. Plates that contain 
progeny that survive indicate that the mother of those offspring contains the desired 
genotype, as the mother would have to have the three needed mutations for ivermectin 
resistance. To double check that this is not a strain containing WT CSR-1, as there is 
another possible progeny that could be ivermectin resistant but not contain the csr-1 
mutation, a PCR protocol designed to target the CSR-1 gene is run of a few of the 
progeny per plate that survive to make sure that the correct strain is found.  
 
 From the now identified correct hermaphroditic mothers of the back cross, more 
of their self-cross hermaphroditic progeny is singled onto as many 35mm NGM plates as 
possible. When these singled hermaphroditic worms start to lay eggs, they are collected 
and run through various PCR protocol to help screen for the correct genotype. These PCR 
protocols tested the homozygosity of the alg-5(ram2), avr-14, glc-1 mutant alleles and 
the heterozygosity of the csr-1 mutant. Four strains were identified as having 
homozygous alg-5(ram2) mutation alongside the csr-1 balanced and ivermectin resistant 
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backgrounds. One of these strains is used in the following ribosomal profiling and 
cloning protocols.  
 
 Unlike the previous cross, no noticeable phenotype was noticed with any of the 
completed mutant strains. Though it is disappointing that a new phenotype wasn’t 
observed, that doesn’t mean that the changes this mutant incurred could not still be 
significant. These csr-1 alg-5(ram2) strains will hopefully identify the role the miR-58 
family has with the CSR-1 dependent germline genes. Data that should be completed 
once the mRNA and small RNA sequencing is complete.  
Brood Size Observations of csr-1 and wago9 Mutants 
 
 After recording the presence of a new phenotype in the csr-1 wago-9 double 
mutant, a test was devised to track and prove the consistency of this new phenotype. This 
brood size experiment was used to track the egg laying and hatching of the new strain 
(csr-1 wago-9 homozygous deletion), the two original strains from the cross (csr-1 and 
wago-9 both homozygous deletion), and a control (avr 3x). All of these strains, including 
the control strain, exist within an ivermectin resistant background and as such were 
singled and grown on ivermectin plates. Recording these other strains, alongside that of 
the csr-1 wago-9 homozygous double mutant, allows for reasonable comparisons for the 
severity of the new phenotype. 
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This ivermectin background is needed due to the csr-1 mutant and the need for the 
existence of a balancer in the strain. As mentioned in the design of the cross, to create the 
double mutant this brood size experiment is meant to test, the csr-1 mutant cannot exist 
as a homozygous mutant and successfully sustain a second generation. So, this ivermectin 
resistance is placed to ensure when it is needed only the homozygous version of this 
strain is what is being tested.  
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 Observations of the first day shows that mutants containing the homozygous csr-1 
deletion had no L1 worms present on the any of the 25 plates. This continues for the 
remaining three days as well (Figure 8A). Maintaining the expected phenotype of this 
deletion mutant, as it would seem these hermaphroditic worms have problems laying 
viable eggs. As it is seen in the csr-1 homozygous mutant, though no L1 worms were 
seen, these plates had the highest concentration of eggs still present on the plates. 
However, the homozygous csr-1 wago-9 double mutant had neither the eggs or the L1 
worms (Figure 8A). The control worms, avr 3x, contained almost a thousand L1 worms 
and almost no remaining eggs on the plates. Showing that the vast majority of the eggs 
laid before the first day hatched (Figure 8A). The wago-9 homozygous deletion had more 
eggs laid on average than the control strain on the first day. Having almost 600 more L1 
worms and 160 more unhatched eggs than the avr 3x control (Figure 8A). At the end of 
the first day of counting, the csr-1 mutant strains produced no living offspring and 
maintained a multitude of unhatched eggs, for the homozygous csr-1 mutant, and the 
homozygous wago-9 mutant appears to produce more offspring than that of the avr 3x 
control (Figure 8A). 
 
 The following days the homozygous wago-9 strain begins a steady decline of the 
amount of L1 worms hatched from the laid eggs and the amount of remaining eggs 
unhatched decreased as well. An opposite pattern appears with unhatched eggs within the 
control strain, as the days went on the amount of eggs left unhatched increased. After a 
peak in L1 worm hatchings on day two of the avr 3x control and then followed a decline. 
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When taken all together the averages of these hatched L1’s between the avr 3x control 
and the homozygous wago-9 mutant strains are nearly identical (Figure 8A). Though the 
unhatched eggs are far fewer in the wago-9 mutant strain than in the control strain. 
Mutant homozygous csr-1 and csr-1 wago-9 double mutant strains continued to show the 
lack the living hatched L1 offspring. Unhatched eggs for the csr-1 homozygous mutant 
drops off dramatically by the second day and then again by the third and fourth day. Seen 
with the initial creation of the csr-1 wago-9 mutant strain during the cross experiments, 
this strain does not produce any eggs throughout the entire four days (Figure 8A & B). 
With the addition of the wago-9 homozygous mutation the previous csr-1 homozygous 
mutation phenotype seems to become exacerbated, having the worms go from producing 
no seemingly viable eggs to absolutely no eggs produced at all. These results indicate that 
the WAGO-9 argonaute may have a yet undiscovered process within the germline of C. 
elegans. This role may be discovered with downstream experiments into the double 
mutant strain.  
 
 The results of the brood size tracking confirm what was previously seen during 
the creation of the csr-1 wago-9 double mutant strain. That being the lack of any eggs 
being laid or any being produced in the hermaphroditic worm’s germline in the 
homozygous mutant. Comparing the csr-1 wago-9 homozygous double mutant strain 
with the csr-1 homozygous strain shows that both do not seem to produce any viable 
offspring, but unlike the csr-1 wago-9 mutant, the csr-1 strain still lays eggs (Figure 8B). 
This phenotype has persisted through this tracking experiment and ever since, leading to 
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the acceptance of this phenotype being a result of the addition of a wago-9 mutation 
within the csr-1 mutant background. Alongside the confirmation of the csr-1 wago-9 
double mutant strain phenotype, the wago-9 mutant strain seemed to exhibit no 
noticeable change between it and the avr 3x control strains progeny count but did have 
less eggs laid on the plates when counting was done (Figure 8B). A closer look at the day 
to day progeny counts between the avr 3x and wago-9 strains reveals that the wago-9 
produces a lot more progeny early on compared to that of the avr 3x control strain (Figure 
8A). This initial burst of progeny is eventually balanced out to that of the avr 3x control 
over the last three days of counting. Previous observations of the homozygous wago-9 
strain have shown that it seems to outpace the WT control in progeny development and 
this may be the first bit of evidence to back up that claim. Though it balances out in the 
long term, in the short term the wago-9 strain seems to produce progeny faster than a 
control strain. Of course, more detailed work will have to be done before this is certain. 
There is also a decrease in eggs remaining on the plates compared to the avr 3x control 
strain. This may be a lesser form of the phenotype exhibited within the csr-1 wago-9 
double mutant strain but this is not known for sure, and it still does not seem to hamper 
the overall production of progeny within the wago-9 strain.  
Polysome Profiles of C. elegan Mutant Strains 
 
 Ribosomal profiling was an approach decided upon due to the location of the 
newly identified 22G small RNA reads, the 3’ UTR. Their position on the 3’ UTR raised 
questions about their function and how to study it. In a biological system there is only 
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one currently known way that the 3’ UTR is read and/or utilized, and that is during the 
process of translation (5). Translation being the biological function that creates the 
proteins used in the system by converting the genetic code read out on mRNA into 
various amino acids in a chain like series (17). The process of translation uses ribosomes 
to translate the mRNA to the specified protein (17). Ribosomal Profiling is a procedure in 
which the actively translating ribosome is stalled on the mRNA template, and then this 
currently translated mRNA is isolated from the rest of the RNA and used in downstream 
Figure 9: The above graphs were generated using the software provided by Brendel, and are generated 
during the sucrose fraction collection. A) Control run of the protocol, with only the sucrose gradient and 
buffer. The initial curve would appear to be caused by the PEB buffer or the sucrose gradient its self. B) 
Avr3x mutant strain C) Homozygous csr-1 mutant strain D) Homozygous wago9 mutant strain E) 
Homozygous csr-1 wago9 double mutant F) Homozygous csr-1 alg-5(ram2) double mutant 
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experiments. Knowing about the location of the new 22G small RNAs being on the 3’ 
UTR, and translation being the biological process recognizing this loci, ribosomal 
profiling would help to shed light on exactly what this 22G small RNA family does to the 
genes they are associated with.  
 
Once the isolation of the ribosomes is complete, the samples are analyzed through 
a sucrose fraction collector and a proprietary program from Brendel. There are six major 
peaks or sections of the graphs produced from the Brendel program (Figure 9). The initial 
peak is present in all runs of the samples, even in the control run. This peaks presence in 
both the control and the sample runs indicates that this specific peak is likely due to a 
reagent found within the resuspension buffer. The next peak witnessed is associated with 
the 40 Svendval Unit (S) subunit of the ribosomes followed by the 60S peak and then the 
80S peak. So, the two peaks following the first represent the two individual subunits of 
the whole ribosome; while the next is the complete ribosomal unit. At the bottom of the 
right-hand side of the 80S peak is where the polysome peaks begin. The polysome peaks 
are seen as multiple peaks of increasing height, and the greater the area under these 
multiple peaks’ correlates to the possible final concentration of the combined polysome, a 
greater area meaning a higher possible concentration and a lower peak a lower possible 
concentration (Figure 9B-F). Following immediately after the multiple peaks of the 
polysome, there is a sharp peak followed by a sharp drop. This represents the oil, 
fluorinert FC-40, being introduced to the tubes and the end of the sample being run 
through the fraction collector (Figure 9A-F). Once the various strains have been 
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processed through the Brendel sucrose fraction collector they are quantified using a 
nanodrop. This is to verify the positions of the peaks correspond to the correct tube 
numbers, and to pool the tubes together that are correctly associated with the polysome. 
This process is done for each sample to allow for the use of the samples downstream. 
Generally, each sample is off by one or two tubes compared to the graphs.  
 
 The amount of worms used through the rest of the runs varied based on the 
mutations the strains contain, some of these actually directly link to difficulty in 
propagation of the strain. The control strain, avr 3x, and the wago-9 homozygous mutant 
showed no signs of problems with propagation which allowed for the highest collection 
of worms for this protocol, 1,000,000 and 1,500,000 worms respectively. Due to the csr-1 
mutations effects on the propagation and growth of the worms containing this mutant, the 
worms collected for these strains was less than that of the previous mentioned mutant and 
control strains. Double homozygous mutant csr-1 wago-9 had 800,000 worms able to be 
used for the protocol, a theory as to why the heterozygous csr-1 version of this double 
mutant strain doesn’t struggle to propagate as much as the single heterozygous csr-1 
mutant may be attributed to the presence of the homozygous wago-9 mutant. As 
mentioned before, the wago-9 homozygous mutant seems to grow and propagate at a 
much higher rate than the WT strain. The homozygous csr-1 mutant strain had only 
650,000 worms for its run shown (Figure 9C). Though there were previous runs 
containing < 500,000 worms. These runs lead to polysome profiles containing 
significantly smaller peaks, especially in the polysome portions (Data not shown). So, 
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with this data it was found that the lowest total worms needed for a successful run of the 
protocol is at least 650,000 worms.  
 
 Starting with the control (Figure 9A) it can be seen that the initial peak is all that 
is shared between the various samples. The missing peaks are only found in samples that 
have been properly process through the ribosomal profiling protocol. A preliminary 
estimation to the amount of polysome that can be recovered from a specific strain can be 
found by checking the area under the polysome peaks. A cursory glance over the graphs 
show that three of the five experimental sample graphs have significantly larger areas 
under the polysome peaks (Figure 9C, E & F). Given that the two strains that have lower 
polysome peaks do not contain a csr-1 mutation, avr 3x control and wago-9 homozygous 
deletion mutant, may show that the CSR-1 argonaute may have a role in mRNA 
regulation. This is not the first time that this argonaute has been noted to regulate mRNA, 
and this may add to the evidence of its possible involvement within the biological process 
of translation. The collected samples from the sucrose fraction collector are checked with 
the nanodrop to ensure that the proper tubes are collected. All tubes associated with the 
areas of the graph that contain multiple peaks in close proximity, which indicate the 
position of the polysome, are pooled together and purified through isopropanol 
precipitation and is then able to be used in the cloning protocols. 
 
 Taken alone the charts produced through this protocol do not show much in terms 
of differentiation between the various strains. The graphs have helped in the preparation 
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of each strains samples for used downstream, to obtain data that can be properly 
analyzed. Though this is not to say that there wasn’t a trend that occurred in the graphs. It 
was noticed that samples containing strains that did not contain the csr-1 homozygous 
mutation had smaller polysome peaks compared to samples that contained strains with 
the csr-1 homozygous mutation. As seen in Figure 2, it is possible that CSR-1 argonaute 
has a role in mRNA regulation. So, these peaks may contain further proof that the CSR-1 
argonaute performs some sort of mRNA regulation on its own gene targets and possibly 
others since these results come from a total lysate of the nematode not just of the 
germline CSR-1 specific targets.  
 
Small RNA and mRNA Cloning of Polysome and Input Samples of C. elegan 
Mutant Strains 
 
 From the isolated and pooled polysome and input samples, mRNA and small 
RNA cloning is performed. These cloning protocols will further isolate a specific RNA 
species from the samples and then amplify that specific species. This further isolation is 
needed due to the nature of how abundant certain RNA species are over other species of 
RNA, referring mainly to rRNA. Ribosomal RNA (rRNA) is the most abundant RNA 
found within a living system, ~80%, and for the samples in their current state is now 
considered an abundant contaminant (19). So, the pooled post-ribosomal profile and input 
samples are further process to remove the abundant rRNA and allow the originally minor 
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species (either mRNA or small RNA in these cases) to be amplified. All this is to allow 
for clean sequence reads downstream.  
 
 Small RNA cloning was performed on just the input samples of the csr-1, avr 3x, 
wago-9, csr-1 wago-9 and csr-1 alg-5(ram2) mutant strains. The polysome samples from 
the ribosomal profiling experiments are excluded due to the purification of the samples 
removing most of the small RNAs and leaving mainly the mRNAs and rRNAs. 
Comparisons between the csr-1, wago-9 and csr-1 wago-9 reads should bring light to the 
CSR-1 dependent genes that 3’ UTRs that are dependent as well on the WAGO-9 
argonaute. Finding genes where the 22G small RNA reads are down-regulated in the  
csr-1 wago-9 mutant over that of the csr-1 mutant will accomplish this.  
 
 The mRNA cloning involves both the input samples and the pooled polysome 
samples. Polysome fractions are included since they contain the actively translated 
mRNAs located in the germline of the csr-1, wago-9, avr 3x, csr-1 wago-9 and  
csr-1 alg-5(ram2). This is important due to the location of the newly discovered 22G 
small RNAs, the 3’UTR. The only known biological process that identifies this region of 
the transcribed mRNA is the act of translation. Since the polysome is a collection of 80S 
ribosomes bound to an mRNA, the collection of the polysome is actually collection of the 
currently translated mRNA in the specified strain. These samples will be sent to be 
sequenced through high throughput sequencing.  
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 Sadly, though the cloning is finished, the results of the high-throughput 
sequencing has yet to be completed. This doesn’t mean that there is not speculation over 
how to compare the samples. The csr-1 homozygous mutants reads compared to the csr-1 
wago-9 homozygous double mutant strain should provide insight into the possible 
functional regulation these new 22G small RNAs are involved in. Comparing the reads 
from the csr-1 mutant to that of the avr 3x control may also add more evidence to the 
ability of CSR-1 regulating its own dependent genes (2). Looking at the reads for the  
csr-1 alg-5(ram2) mutant over that of the csr-1 mutant will bring insight into the possible 
roles of miRNA in this new 22G small RNA family. Due to ALG-5 being involved in the 
biogenesis of miRNA which in turn is involved in many roles within the germline of C. 
elegans, and the removal of it leads to many miRNA families to not be properly created. 
The germline reads from the csr-1 alg-5 (ram2) mutant over that of the csr-1 mutant 
could show how, if at all, the lack of miR-58 effects the 22G small RNA reads (14). This 
could then lead to a better understanding of regulation of these 22G small RNAs in this 
novel small RNA pathway.  
 
Discussion 
 
 During the analysis of reads in a csr-1 homozygous strain of C. elegans a new 
family of 22G small RNAs was observed. This new family resided within the 3’ UTR 
region of many of the CSR-1 dependent genes and so is assumed to be expressed within 
the germline (Figure 2). As these were CSR-1 dependent genes, they are known to be 
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used in the transcription of 22G small RNAs that load onto the CSR-1 argonaute. The 
continued presence of 22G small RNA reads within the 3’ UTR with the depletion of 
CSR-1 in the system raised the question as to what argonaute these 22G small RNAs 
were loading onto and what function do they have within the germline of the C. elegan 
organism.  
 
 Two transgenic worm strains in a csr-1 mutant background, containing either 
WAGO-1 or WAGO-9, were used to help identify which argonaute loads these newly 
identified 22G RNAs. Through the use of immunoprecipitation and high throughput 
sequencing the 22G RNA reads from the input and IP samples were analyzed. Using the 
lab genome browser genes known for being CSR-1 dependent, two specifically were used 
as examples Klp-7 and Pgl-1, were examined and a pattern emerged for the WAGO-9 
argonaute. This WAGO argonaute had at least two-fold more 22G small RNA read 
within the 3’ UTR over its input sample, which indicated that it was indeed the argonaute 
loading this newly identified 22G RNA family (Figure 5).  
 
 Seeing as the argonaute that loads the 22G small RNA, WAGO-9, is now known 
and then discovering miR-58 family has overlapping targets to the 3’ UTRs of the same 
CSR-1 dependent genes (data not shown), mutant strains needed to be made. These 
mutant strains were crossed within a csr-1 mutant and ivermectin resistance background. 
The wago-9 deletion exists as a homozygous null mutant alongside a balanced csr-1 
mutant allele. While the miR-58 family is removed from the worm through the deletion 
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of the ALG-5 miRNA associated protein. This protein is known to me required for the 
biogenesis of many germline-based miRNA, including miR-58 family (14). These mutant 
strains are used downstream for the eventual analysis of small RNA and mRNA reads 
post high throughput sequencing.  
 
 The newly created mutant strains, alongside the csr-1 mutant and avr 3x mutant 
control, were put through the ribosomal profiling protocol to isolate the mRNA currently 
being translated. It was noticed through the graphs created through this process that the 
strains that possessed the csr-1 mutant contained significantly higher peaks than those 
strains that did not contain this mutation (Figure 9B-F). This discovered pattern added 
more evidence to the CSR-1 argonaute possibly having a role in mRNA regulation, as the 
smaller peaks indicate that there is possibly less mRNA available for the 80S ribosomes 
to bind to for translation. This would in turn lead to less mRNA translation, and thus 
smaller polysome peaks. The mRNA transcripts and the input samples are collected and 
run through the mRNA and small RNA cloning protocols. The results of this are to be 
sent out for sequencing once they have been properly pooled together. High throughput 
sequencing will then be performed. From the reads of the small RNA, the role of  
WAGO-9 as the loading argonaute will be proven through the decrease in reads at the 3’ 
UTR and the effect of miR-58 family on the 22G small RNA in the 3’ UTR will be seen. 
Using the resulting reads from the mRNA sequencing a possible target for what these 
22G small RNAs regulate can be deciphered through which genes have upregulated reads 
in the csr-1 wago-9 double homozygous mutant over that of the csr-1 homozygous 
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mutant. The reads from the mRNA cloning will also provide insight into whether CSR-1 
argonaute can actually regulates its target dependent genes and/or other genes.  
 
 Though it would be expected that small RNAs created from loci associated with a 
certain argonaute would be loaded onto said argonaute, this newly identified 22G small 
RNA breaks that mold. This new 22G small RNA family is created from the 3’ UTR of a 
CSR-1 dependent gene, but loads onto the WAGO-9 argonaute. WAGO-9 being one of 
two of the known argonauts in the WAGO family to exist in the germline. The origin of 
these 22G small RNAs also raised a few questions about their possible roles within the 
germline of the C. elegan, originating from the 3’ UTR instead of the CDS. Through the 
future analysis of the reads from the various cloning procedures mentioned previously, 
the reasons to this family’s origin location of biogenesis and its role(s) within the 
germline should hopefully be answered.  
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